•
Feb 28, 2023

Walgreens Q2 2023 Earnings Report

Walgreens' financial results were in line with expectations, and the company remained on track with its full-year guidance.

Key Takeaways

Walgreens Boots Alliance reported a 3.3% increase in sales to $34.9 billion, but experienced a decrease in EPS to $0.81 and adjusted EPS to $1.16, impacted by lower COVID-19 vaccine and testing volumes. The company invested in VillageMD's acquisition of Summit Health and maintained its full-year adjusted EPS guidance.

Second quarter sales increased 3.3 percent year-over-year to $34.9 billion.

EPS decreased 20.3 percent to $0.81, and adjusted EPS decreased 27.2 percent to $1.16.

Invested $3.5 billion in VillageMD’s acquisition of Summit Health.

Maintaining full-year adjusted EPS guidance of $4.45 to $4.65.

Total Revenue
$34.9B
Previous year: $33.8B
+3.3%
EPS
$1.16
Previous year: $1.59
-27.0%
Gross Profit
$7.06B
Previous year: $7.71B
-8.5%
Cash and Equivalents
$1.09B
Previous year: $1.89B
-42.3%
Free Cash Flow
$248M
Previous year: $669M
-62.9%
Total Assets
$100B
Previous year: $92.7B
+8.4%

Walgreens

Walgreens

Walgreens Revenue by Segment

Walgreens Revenue by Geographic Location

Forward Guidance

Walgreens is maintaining its full-year adjusted EPS guidance of $4.45 to $4.65, with expectations of strong core business growth being offset by lapping peak COVID-19 demand. The company anticipates pivoting to mid-twenties percent adjusted EPS growth in the second half of fiscal 2023.